Avanza Fonder AB Purchases New Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Avanza Fonder AB acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 4th quarter, HoldingsChannel reports. The fund acquired 10,408 shares of the biopharmaceutical company’s stock, valued at approximately $7,414,000.

Several other hedge funds have also added to or reduced their stakes in REGN. Fermata Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $207,000. Hennion & Walsh Asset Management Inc. increased its holdings in Regeneron Pharmaceuticals by 3.3% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 3,106 shares of the biopharmaceutical company’s stock worth $2,212,000 after acquiring an additional 99 shares during the last quarter. Outlook Wealth Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at about $305,000. Park Avenue Securities LLC lifted its holdings in Regeneron Pharmaceuticals by 6.9% during the fourth quarter. Park Avenue Securities LLC now owns 2,019 shares of the biopharmaceutical company’s stock valued at $1,438,000 after purchasing an additional 130 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in Regeneron Pharmaceuticals by 2.7% during the fourth quarter. Assenagon Asset Management S.A. now owns 177,604 shares of the biopharmaceutical company’s stock worth $126,513,000 after purchasing an additional 4,745 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN opened at $702.38 on Friday. The stock has a fifty day simple moving average of $744.16 and a two-hundred day simple moving average of $954.41. The company has a market cap of $77.18 billion, a price-to-earnings ratio of 17.38, a price-to-earnings-growth ratio of 1.60 and a beta of 0.10. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $666.25 and a 12-month high of $1,211.20.

Analyst Ratings Changes

REGN has been the topic of several research reports. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Morgan Stanley lowered their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. JPMorgan Chase & Co. cut their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. BMO Capital Markets decreased their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $1,015.38.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.